HMGB1 serum baseline levels of 227 patients undergoing gastrointestinal endoscopy differed significantly between the five created subgroups of nonmalignant diseases, high risk (e.g., adenomas), early gastric cancer, advanced gastric cancer and metastasized gastric cancer. This evidence concerns the gene HMGB1 and gastric cancer.